Diagnosis of Prostate Cancer Annapolis MD

Mass screening for prostate cancer with a test for prostate-specific antigen (PSA) has led to mass over-diagnosis and over-treatment, a new study contends. Since the PSA screening test came into use in 1986, federal government data show that the number of prostate cancer cases in the United States has risen substantially, said the report in the Aug. 31 online issue of the Journal of the National Cancer Institute.

Stanley P Watkins Jr, MD
(410) 573-5300
900 Bestgate Rd Ste 300
Annapolis, MD
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Univ Of Cincinnati Coll Of Med, Cincinnati Oh 45267
Graduation Year: 1964

Data Provided by:
Kathleen Anne Kemmer, MD
(410) 573-5300
900 Bestgate Rd Ste 300
Annapolis, MD
Specialties
Oncology (Cancer)
Gender
Female
Education
Medical School: Univ Of Mn Med Sch-Minneapolis, Minneapolis Mn 55455
Graduation Year: 1996

Data Provided by:
Jeanine Lori Werner, MD
(410) 573-5300
900 Bestgate Rd Ste 300
Annapolis, MD
Specialties
Oncology (Cancer)
Gender
Female
Languages
Spanish
Education
Medical School: Columbia Univ Coll Of Physicians And Surgeons, New York Ny 10032
Graduation Year: 1992
Hospital
Hospital: Anne Arundel Med Ctr, Annapolis, Md
Group Practice: Annapolis Medical Specialist

Data Provided by:
Ashish Kumar Chawla, MD
(443) 481-5800
2001 Medical Pkwy
Annapolis, MD
Specialties
Oncology (Cancer), Radiation Oncology
Gender
Male
Education
Medical School: Jefferson Med Coll-Thos Jefferson Univ, Philadelphia Pa 19107
Graduation Year: 1998

Data Provided by:
Kevin Brian Knopf, MD
(410) 573-5300
900 Bestgate Rd Ste 300
Annapolis, MD
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Univ Of Ca, San Francisco, Sch Of Med, San Francisco Ca 94143
Graduation Year: 1992

Data Provided by:
Jay M Rhee
(410) 573-5300
900 Bestgate Rd
Annapolis, MD
Specialty
Hematology

Data Provided by:
Kevin B Knopf
(410) 573-5300
900 Bestgate Rd
Annapolis, MD
Specialty
Hematology / Oncology

Data Provided by:
Dr.Jason Taksey
(410) 573-5300
2003 Medical Pkwy #210
Annapolis, MD
Gender
M
Speciality
Oncologist
General Information
Accepting New Patients: Yes
RateMD Rating
5.0, out of 5 based on 1, reviews.

Data Provided by:
Robert Dallas Peterson, MD
(517) 548-1246
600 Ridgely Ave
Annapolis, MD
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Jefferson Med Coll-Thos Jefferson Univ, Philadelphia Pa 19107
Graduation Year: 1976

Data Provided by:
Curtis Harris Jr, MD
(410) 897-0083
888 Bestgate Rd Ste 211
Annapolis, MD
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Howard Univ Coll Of Med, Washington Dc 20059
Graduation Year: 1975

Data Provided by:
Data Provided by:

Diagnosis of Prostate Cancer

Provided By:

MONDAY, Aug. 31 (HealthDay News) -- Mass screening for prostate cancer with a test for prostate-specific antigen (PSA) has led to mass over-diagnosis and over-treatment, a new study contends.

Since the PSA screening test came into use in 1986, federal government data show that the number of prostate cancer cases in the United States has risen substantially, said the report in the Aug. 31 online issue of the Journal of the National Cancer Institute.

Treatments for prostate cancer include surgery and radiation therapy, and possible side effects are incontinence and impotency.

"The ideal screening test would have no effect on the number of cases," said study co-author Dr. H. Gilbert Welch, a professor of medicine at the Dartmouth Medical School's Institute for Health Policy and Clinical Practice. "It would change the time in life that the cancers were diagnosed, but not the number. Instead, there has been a sustained change in the number of cases -- 1.3 million more that would not have been diagnosed previously."

The death rate from prostate cancer has fallen in the United States, but not necessarily because of mass screening, Welch contended. "There are a number of reasons why mortality might fall, but the most obvious is that we have better treatment," he said. "Even without early detection, I expect mortality would fall."

Results of a European study reported earlier this year indicated that "to save the life of one man, 50 must be over-diagnosed," he said.

Guidelines for screening for blood levels of PSA -- a protein produced by the prostate gland -- differ widely. The American Cancer Society says that a PSA test should be offered at age 50, accompanied by an explanation of the potential benefits and hazards. The American Urological Association recommends a first PSA test at age 40, with follow-ups depending not only on the test score but also on factors such as ethnicity.

"The recommendations on this are all over the map, and that's because it's a close call," Welch said. "Different people look at the numbers and come to different conclusions. There is the potential to help some people and hurt some people."

In his own medical practice, Welch said, "I try to stay away from this one. If someone asks me, I explain the risks and the benefits."

Given the unknowns, it's entirely appropriate for a man to decide on having a PSA test without advice from a physician, Welch said.

But Dr. Judd Moul, director of the Duke University Prostate Center, after reading the new study, said, "This is not going to change my mind on the issue of screening." Moul recommends an initial PSA test at age 40, with follow-up if necessary.

"We now do have the potential for over-detection, but we still have 30,000 men a year dying from prostate cancer, and the best way to prevent deaths from prostate cancer is still screening," Moul said.

Both Moul and Welch agree that the PSA test is decidedly imperfect because it can't distinguish between the majority of prostate cancers that grow so slowly that they are no danger to a man's life and the fast-growing minority that are potentially fatal and require decisive treatment.

"Right now we don't have that magic biomarker," Moul said. "So I think it is more important to try to reduce the number of deaths than to worry about over-detection."

"I wouldn't expect one to come soon," Welch said, referring to a specific test for virulent prostate cancer. "So we will continue to find a lot of it, and a lot of it that doesn't matter."

More information

Learn about prostate cancer from the U.S. National Cancer Institute.

Author: By Ed Edelson
HealthDay Reporter

SOURCES: H. Gilbert Welch, M.D., professor, medicine, Dartmouth Institute for Health Policy and Clinical Practice, Dartmouth Medical School, Hanover, N.H.; Judd Moul, M.D., director, Duke Prostate Center, Durham, N.C.; Aug. 31, 2009, Journal of the National Cancer Institute, online

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com